Publications
Category: Publications 16 January 2019
Category: Publications 3 April 2018
The role of pharmacology in anticancer drug development.
Co-authored by Hans R. Hendriks
Category: Publications 25 March 2018
Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results
Co-authored by Christian Wolf
Category: Publications 25 March 2018
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Co-authored by Christian Wolf
Category: Publications 8 November 2017
Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer
Co-published by Hans Hendriks
Category: Publications 8 November 2017
Pharmacologically directed strategies in anticancer drug development: from the European NCI Compounds Initiative to academic platform for anticancer drug development
Hendriks HR et al.
Pharmacologically directed strategies in anticancer drug development: from the European NCI Compounds Initiative to academic platform for anticancer drug development. British Journal of Cancer 2017;117:195-202
Category: Publications 6 November 2017
Implementing liquid biopsies into clinical decision making for cancer immunotherapy
Quandt D, Hendriks HR, Zwierzina H and Seliger B.
Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget 2017;8:48507-48520
Category: Publications 2 February 2016
Assay Sensitivity in QT Assessment
J Clin Studies. 2016; 7(6),60-2.
authored by: Richmond Pharmacology
Category: Publications 12 October 2015
Landmark clinical equivalence study in MS
just published and co-authored by Christian Wolf:
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. A Randomized Clinical Trial.
Category: Publications 21 April 2015